Allt inom MAR

We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new patent applications.

The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing the frequency of injections will improve compliance, treatment outcomes, and quality of life for patients.